



**Instructions:**

This form is used by Kaiser Permanente and/or participating providers for coverage of **Amitiza (lubiprostone)**. Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: [1-866-331-2104](tel:1-866-331-2104)]. If you have any questions or concerns, please call [1-866-331-2103](tel:1-866-331-2103). **Requests will not be considered unless this form is complete.**

KP-MAS Formulary can be found at: [Pharmacy | Community Provider Portal | Kaiser Permanente](#)

**1 – Patient Information**

Patient Name: \_\_\_\_\_ Kaiser Medical ID#: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

**2 – Provider Information**

Provider Name: \_\_\_\_\_ Specialty: \_\_\_\_\_ NPI: \_\_\_\_\_

Provider Address: \_\_\_\_\_

Provider Phone #: \_\_\_\_\_ Provider Fax #: \_\_\_\_\_

**3 – Pharmacy Information**

Pharmacy Name: \_\_\_\_\_ Pharmacy NPI: \_\_\_\_\_

Pharmacy Phone # \_\_\_\_\_ Pharmacy Fax #: \_\_\_\_\_

**4 – Drug Therapy Requested**

Drug 1: Name/Strength/Formulation: \_\_\_\_\_

Sig: \_\_\_\_\_

Drug 2: Name/Strength/Formulation: \_\_\_\_\_

Sig: \_\_\_\_\_

**5– Diagnosis/Clinical Criteria**

1. Is this request for initial or continuing therapy?

Initial therapy  Continuing therapy, state start date: \_\_\_\_\_

2. Indicate the patient’s diagnosis for the requested medication: \_\_\_\_\_

**Clinical Criteria:**

1. Prescribed by an Oncologist, Pain Specialist, Gastroenterologist or in consultation with a Gastroenterologist,

No  Yes

2. **AND** member has a diagnosis of irritable bowel syndrome with constipation (IBS-constipation predominant) in women  $\geq 18$  years of age  
 No  Yes

3. **AND** member has had an inadequate response to an adequate trial of at least 4 weeks or intolerance or contraindication to scheduled doses of the following medications:  
- Fiber supplement: psyllium fiber or methylcellulose  
- Polyethylene glycol  
 No  Yes

--OR--

1. Prescribed by an Oncologist, Pain Specialist, Gastroenterologist or in consultation with a Gastroenterologist,  
 No  Yes

2. **AND** member has a diagnosis of chronic idiopathic constipation  
 No  Yes

3. **AND** member has had an inadequate response to an adequate trial of at least 4 weeks or intolerance or contraindication to scheduled doses of the following medications  
- Fiber supplement: psyllium fiber or methylcellulose  
- Osmotic laxative: polyethylene glycol or lactulose  
- Stimulant laxative: senna or bisacodyl  
 No  Yes

--OR--

1. Prescribed by an Oncologist, Pain Specialist, Gastroenterologist or in consultation with a Gastroenterologist,  
 No  Yes

2. **AND** member has a diagnosis of opioid induced constipation in an adult with an active opioid prescription  
 No  Yes

3. **AND** opioid medication is being prescribed by an oncologist or a hospice/palliative care clinician for a member currently enrolled in hospice or palliative care program, or after consultation with a pain management specialist  
 No  Yes

4. **AND** member has failed a trial of at least 2 weeks or has an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action (i.e., osmotic with a stimulant) and route of administration:  
- Polyethylene glycol  
- Lactulose or sorbitol  
- Senna  
- Bisacodyl  
 No  Yes

**For continuation of therapy, please respond to additional questions below:**

1. Member has a positive clinical response to Amitiza  
 No  Yes

**NOTES: If patient meets criteria, please ensure generic is prescribed and dispensed**

**7 – Provider Sign-Off**

**Additional Information –**

- 1. Please submit chart notes/medical records for the patient that are applicable to this request.**
- 2. If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:**

---

---

**I certify that the information provided is accurate. Supporting documentation is available for State audits.**

**Provider Signature:**

**Date:**

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility